NUS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Nu Skin Enterprises Inc (NUS) is not a good buy at this moment for a beginner investor with a long-term strategy. The company is facing significant financial challenges, including a sharp decline in revenue and net income, as well as missing earnings expectations. The technical indicators and options data also do not suggest a strong entry point. Given the lack of positive catalysts and the investor's preference for long-term stability, it is best to hold off on investing in this stock for now.
The technical indicators for NUS show a neutral to bearish trend. The MACD histogram is negative and contracting, indicating weak momentum. The RSI is at 44.602, which is neutral, and moving averages are converging, showing no clear trend. The stock is trading below key pivot levels, with support at $9.967 and resistance at $10.777.
Additionally, it reduced outstanding debt to $224 million and is focusing on long-term growth initiatives like the Prysm iO devices and market expansion in India.
Nu Skin missed Q4 2025 earnings and revenue expectations, with revenue down 16.89% YoY and net income down 140.14% YoY. The pre-market price has dropped by 15.77%, reflecting negative market sentiment. The company's 2026 revenue projection indicates uncertainty, and the high implied volatility suggests significant risk.
In Q4 2025, Nu Skin's revenue dropped to $370.3 million (-16.89% YoY), net income fell to $14.49 million (-140.14% YoY), and EPS declined to $0.29 (-139.73% YoY). Despite these declines, gross margin improved to 70.74% (+12.91% YoY), and the company reduced its debt and generated positive cash flow.
No recent analyst rating or price target changes were provided. However, the company's weak financial performance and missed earnings expectations are likely to weigh on sentiment.
